# Efficiency and Safety Study of Pegylated Somatropin to Treat Growth Hormone Deficiency Children

> **NCT01342146** · PHASE2 · COMPLETED · sponsor: **Changchun GeneScience Pharmaceutical Co., Ltd.** · enrollment: 101 (actual)

## Conditions studied

- Growth Hormone Deficiency

## Interventions

- **DRUG:** pegylated Somatropin
- **DRUG:** pegylated Somatropin
- **DRUG:** Jintropin AQ

## Key facts

- **NCT ID:** NCT01342146
- **Lead sponsor:** Changchun GeneScience Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05
- **Primary completion:** 2007-01
- **Final completion:** 2007-02
- **Target enrollment:** 101 (ACTUAL)
- **Last updated:** 2017-07-31

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01342146

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01342146, "Efficiency and Safety Study of Pegylated Somatropin to Treat Growth Hormone Deficiency Children". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT01342146. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*